CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan and diagnostic advisor Dr Bruce Patterson tell Proactive the companhy has shared a pre-print online version of a manuscript that describes the immunological mechanism through which its flagship drug leronlimab restores immune homeostasis, or balance by reducing “viral load,” and reverses “hyper immune activation” and “inflammation” in critically ill coronavirus patients.
Pourhassan says the Vancouver, Washington- based company says the manuscript will be peer-reviewed, and will show the validity of the study’s findings.
